Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ER niacin/laropiprant add-on to ongoing lipid-modifying therapy in hypercholesterolemia or mixed dyslipidemia
NL-OMON36069Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of niacin and laropiprant in hypercholesterolemia and combined dyslipidaemia, sponsored by Merck & Co. Planned start Aug 2011; status: not yet recruiting.
02
Drugs
niacinlaropiprant
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on NL-OMON36069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36069.